11/4/2026

Janusmed kön och genus

Janusmed kön och genus – Alkéran

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C! C!
C! C!

Melfalan

Melfalan

Klass : C!

Visa all info

Skriv ut

Kontakta oss

  1. Alkeran (melphalan), 2 mg tablet. Summary of Product Characteristics. Swedish Medical Products Agency [updated 2025-01-16, cited 2026-10-04]

  2. Alkeran (melphalan), 50 mg, powder and liquid for solution for injection. Summary of Product Characteristics. Swedish Medical Products Agency [updated 2025-01-16, cited 2026-10-04]

  3. Bird S, Cairns D, Menzies T, Boyd K, Davies F, Cook G et al. Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clin Lymphoma Myeloma Leuk. 2021;21(10):667-675.

  4. Jiang Y, Liang G, Cao Y. Trends in mortality rates associated with multiple myeloma in the United States, 1999-2023. Front Oncol. 2025;15:1735565.

  5. Mougenot P, Pinguet F, Fabbro M, Culine S, Poujol S, Astre C et al. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. Cancer Chemother Pharmacol. 2004;53(6):503-12.

  6. Nath CE, Shaw PJ, Trotman J, Zeng L, Duffull SB, Hegarty G et al. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. Br J Clin Pharmacol. 2010;69(5):484-97.

  7. Shah GL, Boelens JJ, Carlow D, Lin A, Schofield R, Cruz Sitner N et al. Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens. Clin Pharmacokinet. 2022;61(4):553-563.

  8. Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH, Apperley JF, Pohlreich D, Browne PV, Kobbe G, Isaksson C, Lenhoff S, Scheid C, Touzeau C, Jantunen E, Anagnostopoulos A, Yakoub-Agha I, Tanase A, Schaap N, Wiktor-Jedrzejczak W, Krejci M, Schönland SO, Morris C, Garderet L, Kröger N. Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study A report by the EBMT Chronic Malignancies Working Party. Haematologica. 2018;103(3):514-521.

  9. Björkstrand B, Klausen TW, Remes K, Gruber A, Knudsen LM, Bergmann OJ, Lenhoff S, Johnsen HE. Double versus single high-dose melphalan 200 mg/m2 and autologous stem cell transplantation for multiple myeloma: a region-based study in 484 patients from the Nordic area. Hematol Rev. 2009;1(1):e2. doi: 10.4081/hr.2009.e2

  10. Francés Alexandre I, Gea Peña A, Tobalina García A, Domínguez-García JJ, Alejo Alonso E, González-Rodríguez AP et al. Variables Associated With the Risk of Severe Mucositis During Autologous Transplantation in Multiple Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2026;26(1):e50-e56.

  11. Vokurka S, Bystrická E, Koza V, Scudlová J, Pavlicová V, Valentová D et al. Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study. Support Care Cancer. 2006;14(9):974-6.

  12. Gordillo CA, Parmar S, Blanco M, Delille EM, Assal A, Mapara M et al. Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies. Ann Hematol. 2021;100(7):1863-1870.

  13. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]

  1. Alkeran (melphalan), 2 mg tablet. Summary of Product Characteristics. Swedish Medical Products Agency [updated 2025-01-16, cited 2026-10-04]
  2. Alkeran (melphalan), 50 mg, powder and liquid for solution for injection. Summary of Product Characteristics. Swedish Medical Products Agency [updated 2025-01-16, cited 2026-10-04]
  3. Bird S, Cairns D, Menzies T, Boyd K, Davies F, Cook G et al. Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clin Lymphoma Myeloma Leuk. 2021;21(10):667-675.
  4. Jiang Y, Liang G, Cao Y. Trends in mortality rates associated with multiple myeloma in the United States, 1999-2023. Front Oncol. 2025;15:1735565.
  5. Mougenot P, Pinguet F, Fabbro M, Culine S, Poujol S, Astre C et al. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. Cancer Chemother Pharmacol. 2004;53(6):503-12.
  6. Nath CE, Shaw PJ, Trotman J, Zeng L, Duffull SB, Hegarty G et al. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. Br J Clin Pharmacol. 2010;69(5):484-97.
  7. Shah GL, Boelens JJ, Carlow D, Lin A, Schofield R, Cruz Sitner N et al. Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens. Clin Pharmacokinet. 2022;61(4):553-563.
  8. Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH, Apperley JF, Pohlreich D, Browne PV, Kobbe G, Isaksson C, Lenhoff S, Scheid C, Touzeau C, Jantunen E, Anagnostopoulos A, Yakoub-Agha I, Tanase A, Schaap N, Wiktor-Jedrzejczak W, Krejci M, Schönland SO, Morris C, Garderet L, Kröger N. Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study A report by the EBMT Chronic Malignancies Working Party. Haematologica. 2018;103(3):514-521.
  9. Björkstrand B, Klausen TW, Remes K, Gruber A, Knudsen LM, Bergmann OJ, Lenhoff S, Johnsen HE. Double versus single high-dose melphalan 200 mg/m2 and autologous stem cell transplantation for multiple myeloma: a region-based study in 484 patients from the Nordic area. Hematol Rev. 2009;1(1):e2. doi: 10.4081/hr.2009.e2
  10. Francés Alexandre I, Gea Peña A, Tobalina García A, Domínguez-García JJ, Alejo Alonso E, González-Rodríguez AP et al. Variables Associated With the Risk of Severe Mucositis During Autologous Transplantation in Multiple Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2026;26(1):e50-e56.
  11. Vokurka S, Bystrická E, Koza V, Scudlová J, Pavlicová V, Valentová D et al. Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study. Support Care Cancer. 2006;14(9):974-6.
  12. Gordillo CA, Parmar S, Blanco M, Delille EM, Assal A, Mapara M et al. Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies. Ann Hematol. 2021;100(7):1863-1870.
  13. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]